Abstract: The present invention relates to a compound of the formula (I) wherein all of R1 to R11, except one, are independently selected from the group consisting of H, D, F, substituted or unsubstituted C1 to C18 alkyl, substituted or unsubstituted C6 to C42 aryl, substituted or unsubstituted C3 to C42 heteroaryl; and adjacent groups R1 to R11 may be linked to each other to form a fused ring, wherein the one of R1 to R11 not selected from the above groups is a group G, wherein the group G comprises one atom A having an electron pair in a p-orbital thereof; the group G comprises two 6-membered aryl rings which are attached to the atom A, wherein each of the two 6-membered aryl rings is attached to the atom A via a single bond respectively; and wherein the two 6-membered aryl rings attached to the atom A may be connected with each other via a single bond; the group G comprises 12 to 66 carbon atoms in total; the group G is attached to the benzoacridine part of the compound of formula (I) via a single bond or vi

Abstract: The present invention relates to a charge transporting semi-conducting material. The charge transporting semi-conducting material may include optionally at least one electrical dopant, and a branched or cross-linked charge transporting polymer that includes 1,2,3-triazole cross-linking units of at least one of the general formulae Ia and/or Ib herein. The charge transporting polymer can include ethylene building units substituted with at least one pending side group including a conjugated system of delocalized electrons. Also provided herein are processes for obtaining the charge transporting semi-conducting material.

Abstract: The invention relates to an electronic device comprising a compound having Formula (1): ABx (1), wherein A is a structural moiety that consists of at least two atoms and comprises a conjugated system of delocalized electrons, each B is independently selected from an imine functional group (1a), wherein R1, R2, R3, R4 are independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C3 alkinyl, C3-C30 cycloalkyl, C6-C30 aryl, C2-C30 heteroaryl, C7-C30 arylalkyl, C3-C30 heteroarylalkyl, the wave line represents a covalent bond to the imine nitrogen atom, G is in each group (1a) independently selected from a quarternary carbon atom and from a cyclopropenylidene structural moiety, x is an integer equal one or higher, preferably equal two or higher, and the lone electron pair of the imine nitrogen atom and/or the pi-electrons of the imine double bond of at least one group B is conjugated with the conjugated system of delocalized electrons comprised in the structural moiety A, with the proviso that two or more of th

Abstract: The present invention relates to a method for preparing an organic semiconductor layer in a vacuum chamber at a pressure of 10?5 to 10?9 mbar comprising a step of sublimating a composition from a single vacuum thermal evaporation source arranged in the vacuum chamber, wherein the composition comprises a physical mixture of (a) a first organic aromatic matrix compound having a molecular weight ?400 and ?1,000: and (b) a first alkali organic complex having a molecular weight of ?100 and ?400.

Abstract: The present invention relates to a charge transporting semi-conducting material comprising: a) at least one electrical dopant, and b) a branched or cross-linked charge-transporting polymer comprising cyclobutenone cross-linking units of at least one of the general formulae la and/or lb, wherein aa) Pol1, Pol2, Pol3 and Pol4 are independently selected chains of the charge-transporting polymer, bb) X1, X2, X3, and X4 are independently selected optional spacer units or, independently, represent direct bonding of Pol1, Pol2, Pol3 and Pol4 chains to the cyclobutenone ring, cc) Z1, Z2, Z3, and Z4 are independently selected from H, halogen or a carbon-containing group; the charge transporting semi-conducting material being obtainable by a process comprising: i) providing a solution containing aaa) at least one precursor charge transporting compound comprising at least one covalently attacked alkenyloxy group having generic formula II wherein X is an optional spacer which is further linked to a charge transporting st

Abstract: The present invention relates to a charge transporting semi-conducting material. The charge transporting semi-conducting material may include optionally at least one electrical dopant, and a branched or cross-linked charge transporting polymer that includes 1,2,3-triazole cross-linking units of at least one of the general formulae Ia and/or Ib herein. The charge transporting polymer can include ethylene building units substituted with at least one pending side group including a conjugated system of delocalised electrons. Also provided herein are processes for obtaining the charge transporting semi-conducting material.

Abstract: The invention relates to an electronic device comprising a compound having Formula (1): ABx (1), wherein A is a structural moiety that consists of at least two atoms and comprises a conjugated system of delocalized electrons, each B is independently selected from an imine functional group (1a), wherein R1, R2, R3, R4 are independently selected from C1-C30 alkyl, C2-C30 alkenyl, C2-C3 alkinyl, C3-C30 cycloalkyl, C6-C30 aryl, C2-C30 heteroaryl, C7-C30 arylalkyl, C3-C30 heteroarylalkyl, the wave line represents a covalent bond to the imine nitrogen atom, G is in each group (1a) independently selected from a quarternary carbon atom and from a cyclopropenylidene structural moiety, x is an integer equal one or higher, preferably equal two or higher, and the lone electron pair of the imine nitrogen atom and/or the pi-electrons of the imine double bond of at least one group B is conjugated with the conjugated system of delocalized electrons comprised in the structural moiety A, with the proviso that two or more of th

Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.